In this video, Dr. David Valle, Professor and Director of the Institute of Genetic Medicine at Johns Hopkins University School of Medicine, discusses the advancement of evolutionary medicine and also speaks about the Johns Hopkins Individualized Medicine Program.
In this video, Dr. David Valle, Professor and Director of the Institute of Genetic Medicine at Johns Hopkins University School of Medicine, discusses the advancement of evolutionary medicine and also speaks about the Johns Hopkins Individualized Medicine Program.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More